Batch variation in SS-31: results from repeat sampling
2 independently tested samples across 2 companies, and what the results say about SS-31.
Testing ReportSS-31
Also known as: Elamipretide, MTP-131
Moderate evidence
ClassMitochondria-targeting tetrapeptide
Research statusPhase 3 clinical trials
Independent tests2
Studies indexed2
Companies tested 2
Overview
A cardiolipin-binding tetrapeptide studied in primary mitochondrial myopathy and Barth syndrome.
SS-31 is classified as a mitochondria-targeting tetrapeptide. Its current development status is: phase 3 clinical trials. Human trial data exists but is limited in size, duration or independence; conclusions should be held loosely.
The Peptide Institute tracks SS-31 because it is actively sold through research-compound and telehealth channels. Our interest is narrow and specific: what is actually in the vial, whether the label is accurate, and whether the sellers of it can document what they claim. We take no position on whether anyone should use it.
Independent Testing
Independently tested companies that sell SS-31
Every company below was evaluated with product the Institute purchased anonymously and sent for third-party laboratory analysis. Ranked by Index Score™.
- Companies
- 2
- Samples
- 2
- Updated
- Aug 17, 2026
- 1 Lumen Research Supply Excellent Institute
Top Rated SS-3197.7% average purity across 1 sample
Purity & Testing 99 Transparency 80 Samples 1 89 View company - 2 NextGen Peptides Excellent
97% average purity across 1 sample
Purity & Testing 91 Transparency 80 Samples 1 85 View company
Research & Studies
Studies library-
Long-term outcomes with SS-31: an open-label extension
Reports findings relevant to the primary claims made for SS-31; sample size limits how far the result generalises.
-
SS-31: dose-ranging efficacy and safety findings
Adds to the SS-31 evidence base without resolving the central question of human efficacy.
Independent Testing
Testing databaseLaboratory verification of SS-31 products across the companies we index.
SS-31 Lumen Research Supply
Purity 97.7% Verified
SS-31 NextGen Peptides
Purity 97.0% Verified
Latest Coverage
SS-31 enters a new trial phase, the questions it still has to answer
A close reading of the SS-31 evidence, without the marketing layer.
News
The SS-31 market in 2026: who is actually selling it
Purity across our SS-31 samples ranged from 97% to 97.7%. Here is the context.
Industry AnalysisCommunity Discussions
Forum 71 replies
56 replies
6 replies
The Peptide Institute Weekly
Research. Testing. Regulation. No hype.
One email a week: new study summaries, the latest independent lab results, ranking movements, and regulatory developments that matter.
- New research, summarized in plain English
- Independent lab results as they publish
- Score and ranking movements